An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ertaş Faruk, Kaya Hasan, Yıldız Abdulkadir, Davutoğlu Vedat, Kiriş Abdulkadir, Dinç Lale, Kafes Habibe, Avcı Anıl, Calapkorur Bekir, Ertaş Gökhan, Gül Mehmet, Kahraman Ay Nuray, Bulur Serkan, Durukan Mine, Eren Murat, İlhan İbrahim, Küçük Murathan, Özpelit Ebru, Şimşek Hakkı, Uçar F Mehmet, Yıldız Ahmet, Şahin D Yıldıray, Ayhan Erkan, Çağlayan C Emre, Güngör Hasan, Özyurtlu Ferhat, Şen Nihat, Vatan Bülent, Vatansever Fahriye, Kobat Mehmet Ali, Temiz Ahmet, Taylan Gökay, Dönmez İbrahim, Erkuş M Emre, Söylemez Selami, Zengin Halit, Gündüz Mahmut, Tuncez Abdullah, Karavelioğlu Yusuf, Gökdeniz Tayyar, Koza Yavuzer, Aktop Ziyaeddin, Katlandur Hüseyin, Karaca Özer Pelin, Yüksel Murat, Acet Halit, Çil Habib, Alan Sait, Toprak Nizamettin
Аннотация
STUDY DESIGN: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization).
RESULTS: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016.
CONCLUSION: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials.gov number, NCT02354456.).